4D Molecular Therapeutics (FDMT) Preferred Stock Liabilities (2019)
4D Molecular Therapeutics (FDMT) reported Preferred Stock Liabilities of $103.0 million for Q4 2019.
4D Molecular Therapeutics (FDMT) has 1 years of Preferred Stock Liabilities data on file, last reported at $103.0 million in Q4 2019.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $103.0 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $103.0 million (changed N/A YoY) and the FY2019 annual result came in at $103.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities held at $103.0 million in Q4 2019 per FDMT's latest filing.
- Across five years, Preferred Stock Liabilities topped out at $103.0 million in Q4 2019 and bottomed at $103.0 million in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | 4D Molecular Therapeutics | 674.52 Mn | 674.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 102.98 Mn |